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Abstract
Background: In Australia, the Pharmaceutical Benefits Scheme (PBS) has developed a set of
arrangements to control access to high-cost medicines to ensure their use is cost-effective. These
medicines include the tumour necrosis factor-alpha inhibitors (TNFIs) for the treatment of
rheumatoid arthritis. The aim of this first phase of a qualitative study was to explore basic views on
the restricted access to TNFIs in order to confirm where further investigation should take place in
the next phase.
Methods: Semi-structured interviews were conducted in 2004 with a member of the four relevant
stakeholder groups. Participants were asked their opinions about features of the establishment,
process and effects of the system of restricted access to TNFIs. Views on the collaboration
between stakeholder groups in the decision-making process were also collected.
Results: The principle of 'controlled access' to TNFIs was supported in general. There were
concerns regarding some of the specific eligibility criteria. Wider and more transparent stakeholder
consultation was judged desirable. Some flexibility around prescribing of TNFIs by physicians, and
regular review of the arrangements were proposed. These themes will inform the next phase of
the study.
Conclusion: This first phase highlighted a range of issues associated with the PBS arrangements
restricting access to TNFIs. Timely review and report of issues and concerns associated with such
policy developments that arose in practice are essential. There is a need for a more comprehensive
exploration across a wide range of stakeholders with different perspectives that will in turn be
helpful in guiding policy and practice around national arrangements to manage access to high-cost
medicines.
Background
Expenditure on pharmaceuticals has increased dramati-
cally in all countries both in the developed and the devel-
oping world in recent years [1]. Provision of an increasing
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number of effective but expensive pharmaceuticals by
drug reimbursement systems is challenging because the
costs per patient are high. Payers in the public and private
health systems face similar challenges due to increasing
consumer expectations to access these medicines in the
context of substantive cost constraints. The Pharmaceuti-
cal Benefits Scheme (PBS) is Australia's national program
which provides subsidised access to prescriptions medi-
cines for the community [2]. Decisions on drug reim-
bursement ('listing') under the PBS are based on
assessment by the Pharmaceutical Benefits Advisory Com-
mittee (PBAC), which evaluates efficacy, safety and incre-
mental cost-effectiveness of new pharmaceutical products
compared to other existing treatments [3]. Australia was
the first country to introduce an explicit requirement for
economic analysis to select pharmaceuticals for a publicly
funded formulary [4]. This system has attracted consider-
able attention worldwide as Australian pharmaceutical
prices are markedly lower than those in other comparable
countries [5]. The national goal, as expressed in Australia's
National Medicines Policy and, in particular, the Quality
Use of Medicines component, states that limited resources
should be utilised in such a way that there is provision of
needed, effective and safe medicines that are affordable
for the individual in order to achieve optimal health out-
comes [6].
Biological agents licensed in Australia for treating rheu-
matoid arthritis include three tumour necrosis factor-
alpha inhibitors (TNFIs), etanercept (Enbrel®), infliximab
(Remicade®), and adalimumab (Humira®), and an inter-
leukin-1 receptor antagonist, anakinra (Kineret®). These
new medicines markedly reduce disease activity in a
majority of patients, but there are concerns about their
high cost (approximately AUD$20,000 per patient per
year), in particular given the annual growth in govern-
ment expenditure on pharmaceuticals averaging 10.5%
between 1992–93 and 2002–03 (representing an increase
from AUD$1.88 billion to AUD$5.12 billion) [7]. Fur-
ther, there are uncertainties regarding their long-term
safety, including serious and opportunistic infections and
the risk of lymphoma [8,9].
The PBS has evolved a set of arrangements to control
access to high-cost medicines in an attempt to maintain
the viability of the PBS. Representative, but most innova-
tive of this set of arrangements are those established for
the TNFIs, implemented since August 2003. The decision
to subsidise TNFIs was based on a collaborative decision-
making model to enable the listing of the TNFIs on the
PBS. This involved the PBAC which consulted the relevant
key stakeholders: the respective pharmaceutical compa-
nies, and rheumatologists via the Australian Rheumatol-
ogy Association Therapeutics Subcommittee. The
arrangements for access under the PBS (PBS-restrictions),
formulated to secure the most cost-effective use of these
expensive agents, were agreed upon after extensive negoti-
ations [3,10]. The respective consumer organisation, the
Arthritis Foundation of Australia, also coordinated a
strong lobbying effort by consumer representatives to the
government. This collaborative model has set a new para-
digm for future PBS decisions. Subsidised access was lim-
ited to a subset of patients whose disease "has not been
adequately controlled using conventional anti-rheumatic
drugs and these patients must meet strict criteria for both
starting and continuing biological therapy" [11]. Patients
are required to sign a Patient Acknowledgement Form
which specifies that continuation of therapy beyond four
months "will only be approved if objective, substantial
response is achieved". Prescribing rights are limited to
specialists with expertise in the management of rheuma-
toid arthritis. Also agreed upon was a risk-mitigation
arrangement between the government and the sponsors
that established a ceiling level for government outlays
annually [10]. Similarly complex arrangements for access
are being applied to other high-cost medicines such as
imatinib (Glivec®) for the treatment of patients with
chronic myeloid leukaemia [11].
Decision makers' and stakeholders' perspectives on prior-
itising decisions about drug reimbursement and decision-
making processes in comparable countries such as Fin-
land, Canada, and the United Kingdom have been
described [12-14]. However, to the best of our knowledge,
there are no published data on perceptions regarding
approaches used in Australia, such as arrangements for
access to high-cost medicines operated through the PBS,
or studies examining stakeholder consultation processes
to reach consensus on arrangements for subsidised access
to high-cost medicines. We considered that careful exam-
ination of the recent developments in targeting access to
high-cost medicines, using TNFIs as an example, would be
instructive in informing the debate concerning the princi-
ples and processes that might underpin appropriate and
ethical access to expensive pharmaceuticals under the PBS
or similar access systems. Stakeholders are defined here as
groups of people that have the potential to influence the
decisions on the arrangements for access, or those who are
affected by the PBS-restrictions. The views, attitudes, con-
cerns, and level of support for these arrangements by the
stakeholders are critical determinants for a successful
implementation of the arrangements. Qualitative tech-
niques are useful to explore perceptions and experiences
across a range of relevant stakeholders with respect to
restricted access to TNFIs, and to understand the effects of
the access criteria when implemented in practice. From a
policy perspective, issues and concerns that arise in prac-
tice need to be reviewed in a timely manner thereby ena-
bling appropriate management of any implications.
Research guiding policy development can often best beAustralia and New Zealand Health Policy 2005, 2:28 http://www.anzhealthpolicy.com/content/2/1/28
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undertaken as an iterative approach with each phase
building on the one before, in particular where the impact
of implementing new access criteria on practice is
unknown. The scope and content of such a study are not
specified in advance but are developed iteratively. This
paper reports on the initial phase of a qualitative study
using an iterative approach. This first phase sought to
explore the views of one member of each of the four stake-
holder groups with a vested interest in any new policy
about provision of medicines, in order to confirm where
further exploration should take place in the next iteration.
Methods
Qualitative techniques were used for data collection and
analysis. In depth, semi-structured interviews were con-
ducted in Sydney in 2004 with four individuals to explore
four different perspectives about access to TNFIs under the
PBS. Interviewees were asked their opinions about fea-
tures of the establishment, process and effects of the
arrangements for targeting access to TNFIs. Views on the
decision-making process and collaboration between
stakeholder groups were also collected.
Due to a finite number of key stakeholder representatives
who participated in the PBAC decision-making process
that formulated the arrangements for access to TNFIs, they
were purposively not invited in this initial phase of the
study. Purposeful sampling was used to select participants
on the basis of their primary membership of different
stakeholder groups with respect to the controlled access to
TNFIs: a rheumatologist, a health advisor to the govern-
ment, an employee of a pharmaceutical company, and a
patient (who had used a TNFI). Representation of partici-
pants was not sought in this first phase of the study which
aims to elicit a basic viewpoint from a member of each
stakeholder group. The rheumatologist received an invita-
tion to participate through an opinion-leader rheumatol-
ogist, purposively selected to have had experiences
prescribing TNFIs through the PBS at the time of the
study. The health advisor who participated belonged to a
like-group of the PBAC, and the pharmaceutical employee
was invited to give views of the industry but was not from
a company that marketed TNFIs. The patient was nomi-
nated by a rheumatologist. Participant information sheets
and consent forms were provided to all participants prior
to the interviews. These four interviews were conducted by
one trained researcher (CL); interviews were of 45 to 60
minutes duration.
Interviews were recorded and transcribed verbatim. The
transcripts were coded for major concepts. Categories
related to the discussion topics were created. Coded seg-
ments were then analysed and categorised thematically,
thereby developing a thematic framework. NVivo soft-
ware 2.0 was used to help manage the qualitative data.
The transcripts were also coded independently by another
investigator (RD or KW). The researchers then met to
examine the analyses in order to reach agreement on cat-
egories and identified themes. Some differences with
regard to labelling the themes were found, but agreement
was reached on the central meanings. Interviewees were
offered opportunities to review an edited interview tran-
script to check that their views had been accurately repre-
sented. Only one interviewee reviewed the transcript. It
was accepted without change. The study was approved by
the Human Research Ethics Committees of St Vincent's
Hospital Sydney, and the University of New South Wales,
Australia.
Results and Discussion
This initial phase identified a range of concerns, as held by
individuals from different stakeholder groups, that arose
in practice associated with the recent developments to
control access to a group of high-cost medicines in Aus-
tralia. These are imperative issues that decision makers in
Australia and other countries need to consider and man-
age appropriately and in a timely manner. The pre-deter-
mined interview topics and major themes that emerged
from the data are listed in Table 1. The four major themes
are described below with selected quotes from partici-
pants.
1. Access to medicines
1.1 Targeting access
Interviewees expressed an understanding for the finite
resources that can be allocated to treat the possible range
of diseases. The principle of 'controlled access' to TNFIs
was supported in general. All perceived that the purpose
of restricting access to TNFIs was to control costs while tar-
Table 1: Major themes around restricted access to tumour 
necrosis factor inhibitors
Predetermined Interview topics
Perceptions of PBS-restrictions on access
Experience with application process
Pre-PBS collaboration between the different stakeholder groups
Post-PBS collaboration between the different stakeholder groups
Sources of information
Major themes emerging from data
Access to medicines
Targeting access
Review of the PBS-restrictions
Implications of access arrangements in practice
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geting those patients identified by the access criteria as
most likely to derive benefit.
"The government is trying to target the therapy to those
who need it ... and control their budget." (advisor)
The PBS-restrictions on access, including the limiting of
prescribing rights to qualified specialists, were considered
to be safe and cost-effective, generally evidence-based and
appropriate, given the expense and some lingering uncer-
tainty about long-term safety.
"TNF inhibitors are fairly new ... there are no long-term
data as yet on their use ... they are not without side effects,
and because of their expense, trying existing therapies first
is a reasonable approach" (rheumatologist)
Participants disagreed with some of the specific eligibility
criteria which they interpreted as inflexible and not obvi-
ously evidence-based. For example, a number of patients
with severe rheumatoid arthritis suffered because of the
requirement that rheumatoid factor be positive.
"The requirement for a rheumatoid factor is a concern
because I don't believe that there's any scientific evidence
... and they [application assessors] seem to be inflexible
about that criterion ... There are unfortunate people who
would qualify on every criteria except rheumatoid factor
alone." (rheumatologist)
1.2 Review of the PBS-restrictions
Availability of TNFIs through the PBS, although tightly
restricted, was welcomed. However, ongoing review of the
PBS-restrictions in accordance with emerging new evi-
dence and analysis of utilisation data was seen as both
important and necessary. Interviewees believed the key
stakeholder representatives who had participated in the
initial stakeholder consultation should again participate
in these activities. The risk-mitigation agreement should
also be reviewed for its effectiveness and value.
"There should be some process of review of criteria, after
some agreed period, particularly if they're sharing a
[financial] risk, to see whether they still continue as
appropriate based on new evidence and data of utilisa-
tion, etcetera." (advisor)
2. Implications of access arrangements in practice
2.1 Effects on the practice of rheumatology
The arrangements for access to TNFIs requiring evidence
of exposure to and failure of a number of anti-rheumatic
drugs appear to have promoted re-evaluation of previous
treatments and responses in patients with insufficiently
controlled rheumatoid arthritis. A proportion of patients
may have benefited from this process with better control
of their disease without reaching the 'disease activity' spec-
ified in the eligibility criteria.
"It's forced our rheumatologists to re-look at the treat-
ment that patients have already received and to re-evalu-
ate ... in reassessing the patient and aiming to meet the
PBS criteria, they actually get their rheumatoid arthritis
under control before requiring a biological..." (rheuma-
tologist)
2.2 Ethical issues
One of the ethical issues raised by the interviewees was the
possible benefit that might be achieved in some patients
if the PBS-restrictions would allow a switch to another
TNFI if they failed to respond to the first agent.
"If patients didn't meet the criteria for continuing treat-
ment and at the time they stopped, were not bad enough
to meet the initial criteria for another agent, they can't
switch to another agent, because they are required to meet
the initial criteria again." (rheumatologist).
The original PBS-restrictions did not address this issue,
but these have been altered shortly after the completion of
this study's initial phase. The PBS introduced an 'inter-
changeability' rule from December 2004, allowing
patients who meet the eligibility criteria for commencing
therapy to trial any of the listed TNFIs as well as anakinra,
another anti-rheumatic biological agent [11]. This change
demonstrates that some review of the PBS-restrictions is
occurring.
Despite the 'objective' clinical measures upon which con-
tinued access to TNFIs is determined, there are many fac-
tors influencing the medical condition of an individual.
Concerns were raised about withdrawing patients from an
effective treatment when they may have just missed the
threshold for continued access as well as a lack of flexibil-
ity for physicians to make decisions in cases that are
equivocal based on their professional judgement.
"There's a disparity between the patients' clinical response
and joint count and their laboratory parameters ... the
inflammatory markers may be staying up when they actu-
ally clinically are a lot better." (rheumatologist)
"There's got to be a level of discretion there to the experts
because they're the guys who know. It's not some bureau-
crat." (patient)
The application process was seen to be complex, time-
consuming and an administrative burden for everyone
involved:Australia and New Zealand Health Policy 2005, 2:28 http://www.anzhealthpolicy.com/content/2/1/28
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"The administrative burden for the doctors, for the Health
Insurance Commission...on the pharmacists, and also the
patients...and the whole being caught up in that bureau-
cratic tangle." (pharmaceutical employee)
Another ethical concern was that a Patient Information
Sheet had not been developed to accompany the Patient
Acknowledgement Form at the time these interviews took
place, i.e. 12 months after the first TNFI was made availa-
ble under the PBS.
"They're [the patients] signing a contract and they should
be able to understand the benefits and also the implica-
tions...they need to do it in a manner where they have all
the information they need to decide." (advisor)
2.3 Roles and responsibilities
Broadly, government is expected to provide affordable
access to effective medicines for patients with medical
needs while using taxpayers' money wisely and appropri-
ately. A related and necessary responsibility of govern-
ment is to monitor the PBAC process to ensure
appropriate assessment and selection of medicines for
reimbursement by the PBS.
"The government has an obligation to ensure that the
processes that the PBAC uses are rigorous, are regularly
evaluated, and are well supported." (advisor)
The pharmaceutical industry interviewee felt that infor-
mation provision by industry was a major responsibility
and needed particularly when high-cost medicines subject
to complex eligibility criteria become available through
the PBS. This interviewee considered that updates should
be provided to prescribers about the clinical uses of med-
icines, including the application procedures for PBS-sub-
sidised treatment; and to promote marketing and
publicity with the content being concordant with the PBS-
restrictions (A consequence of risk-mitigation agreements
is a strong negative incentive for inappropriate marketing
and publicity leading to use outside approved PBS-restric-
tions). The risk-mitigation agreement that is part of the
arrangements for access to TNFIs is an indication of col-
laboration between the government and the pharmaceuti-
cal company.
Physicians have a responsibility to comply with the PBS-
restrictions by law [15]. The PBS-restrictions were worded
in such stringent and exhaustive detail that they were seen
to demonstrate a lack of faith in the prescribers by the
PBS.
"There seems ... mistrust from the PBS that rheumatolo-
gists could have a loophole for the prescribing ... that
they're worried that we will be prescribing the drug for
patients who don't strictly have rheumatoid arthritis."
(rheumatologist)
A view was put that if physicians disagree with any of the
restrictions, they should lobby through their professional
organisation for revision because they are ultimately
responsible for their patients' well-being. More reliance
on physicians was considered appropriate and desirable.
"Prescribers are obliged to adhere to the PBS arrange-
ments... If we don't like the criteria and have concerns
with it then the appropriate thing is to lobby through the
ARA [Australian Rheumatology Association]..." (rheuma-
tologist)
Concerns were voiced about the need to achieve substan-
tial clinical improvement for continuing access at the fol-
low-up assessment. This requirement may have
introduced potential perverse incentives to 'fudge' meas-
urements of disease activity in order to ensure continued
access to TNFIs. This raises the issue of the responsibility
and accountability of prescribers with respect to their legal
obligation to comply with the PBS requirements for PBS-
subsidised treatments. However, this does place powerful
ethical concerns on doctors in cases where they become
the agents whereby patients are denied or withdrawn from
effective medicines, particularly if the patient's response is
near the threshold level of eligibility. The Australia Rheu-
matology Association was seen to be responsible for
reviewing the PBS-restrictions and providing information
to their members, i.e. rheumatologists, as well as the
patients.
"The ARA [Australia Rheumatology Association] has an
obligation to provide information to their own members,
it's essential that they support with adequate provision of
education and advice and support about this new treat-
ment ... and they also have a role to provide education to
the public." (rheumatologist)
The role and responsibilities of patient organisations were
not explored in detail in this initial phase. Consumer
organisations could represent patients in the consultation
processes, but qualifications of the staff working in such
organisations were thought to be important if they are to
contribute to the consultation processes or to produce
educational information. Consumer organisations were
perceived to primarily interact with patients and to dis-
seminate information.
"It's difficult to allocate the Arthritis Foundation a more
active role in making recommendations, depending on
who is actually staffing the Arthritis Foundation and
where those opinions are coming from...the ArthritisAustralia and New Zealand Health Policy 2005, 2:28 http://www.anzhealthpolicy.com/content/2/1/28
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Foundation is primarily interfacing with the patients."
(rheumatologist)
The staff at the Health Insurance Commission, a statutory
organisation administering the PBS and other health pro-
grams [16], was considered in general to be helpful with
respect to queries regarding the application procedure for
subsidised TNFI treatments.
3. PBS Decision-making process
3.1 Stakeholder consultation process
The interviewees were in substantive accord with the initi-
ative instituted with TNFIs, that negotiations between the
stakeholders should take place early in the decision-mak-
ing process to enhance the likelihood that the final
arrangements for access to such medicines are reasonable
and can be supported.
"Negotiations should start early so that there is clear com-
munication between the expectation and the calibre of
evidence needed." (advisor)
"...so that the final criteria are the correct criteria, the right
patient group is being identified, and also the initiation
and continuation rules, etcetera, are workable and man-
ageable" (pharmaceutical employee)
However, the interviewees had different views about the
stakeholder consultation process that had taken place.
"The major strength is the negotiations and the partner-
ing." (advisor)
"It seems that each group has their own agenda and it's
not really like a collaboration but more each trying to put
forward their opinion." (rheumatologist)
While the representativeness of the Australian Rheumatol-
ogy Association Therapeutics Sub-committee in the deci-
sion-making process was believed to be appropriate, a
wider consultation among ordinary members of the asso-
ciation was wanted:
"The therapeutics committee should have sought infor-
mation from the members of the ARA [Australian Rheu-
matology Association], or have consulted more widely
before they made their decisions because it seems that
they made their decisions on our behalf but without con-
sulting us." (rheumatologist)
On the subject of representing the views of patients in
such processes, the rheumatologist was of the opinion
that doctors would appropriately represent the views of
their patients. On the contrary, the three other partici-
pants felt that patients should have a more direct role in
the process, which could provide a humane view; and
patients should at least be involved in the development of
the Patient Acknowledgement Form.
"No one really understands what you go through except
you ... not even my rheumatologist or other specialist."
(patient)
"Patient groups should have a seat at the table...they
should be represented formally, rather than by the doc-
tors... We need to have a process where consumers, pre-
scribers, people with interest, come together on an equal
footing to discuss what the issues are and what the criteria
are and can follow the progress." (advisor)
There is increasing need for the voices of patients, their
carers and the public to be heard because it is appropriate
and crucial for acceptance, change and improvement in
the process [17-19]. The representativeness of some con-
sumer groups was raised along with concern that some are
funded in part by pharmaceutical companies. This con-
cern may be reduced if conflicts of interests are declared
openly, which links to the theme of "transparency".
3.2 Transparency
Transparency of the PBAC process and their decisions was
a recurrent theme in the interviews. Interviewees thought
that wider involvement in the consultation process and
greater empowerment of stakeholders to contribute to dis-
cussion of the issues would be desirable. Disclosure of the
rationale behind the PBAC's selection of access criteria,
currently not available in the public domain, was consid-
ered to be desirable and a helpful improvement to the sys-
tem. Greater empowerment (and transparency) by
provision of appropriate information was proposed.
"A public document which summarised why different
decisions were made, and the evidence base on which
they were made would be a most fruitful thing to help
patients to understand why they have potentially limited
access to some of these medicines ... that's about empow-
erment in information." (advisor)
In addition, the issue of the requirement for a positive
rheumatoid factor has been the subject of debate since the
PBS-restrictions for TNFIs were implemented [20,21].
Greater transparency would be helpful to resolve these
concerns and gain increased community support. The
recent recommendation by PBAC to remove this criterion
[22] is a welcome and rational outcome of the lengthy
debate on this issue.
The interviewees who participated in this study were 'out-
siders' to the consultation process that led to establish-
ment of the arrangements for access. MinimalAustralia and New Zealand Health Policy 2005, 2:28 http://www.anzhealthpolicy.com/content/2/1/28
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involvement in the decision-making process and the cur-
rent level of transparency around PBAC's decisions lim-
ited their support for some of the eligibility criteria.
Further, their minimal awareness of the negotiations that
took place between key stakeholders suggests that there is
a need for better communication between those key stake-
holder representatives with their constituencies. Increased
communication within and between the stakeholder
groups is also critical to obtain stronger support for the
final PBS-restrictions in practice.
4. Information provision
The PBS-restrictions to control access to high-cost medi-
cines, exemplified by TNFIs, are particularly complex, and
thus adequate provision of information is all the more
important. Information from pharmaceutical companies
to the prescribers and general practitioners were noted to
be abundant, however, interviewees considered that the
content needed to be more balanced. In particular, the
rheumatologist and the government advisor expressed a
lack of faith in the pharmaceutical companies' ability to
supply appropriate materials for patients or the public.
"It is not the sponsor's responsibility to talk to patients
because they will always get it wrong... direct-to-consumer
advertising is a crazy way to go..." (advisor)
Some concern was also expressed about industry-funded
'educational' functions:
"The way it was presented was one-sided, that the govern-
ment has put all these barriers forward, the barrier nature
was highlighted..." (advisor)
Interviewees' had concerns about the understanding of
the PBS system and the PBAC process among health pro-
fessionals and in the community. Better provision of
information on the structure of the PBS and the PBAC
process was proposed. In particular, interviewees noted
that doctors are the most appropriate health professionals
to inform patients with regards to the PBS-restrictions,
and that they therefore need to be better informed about
the cost-effective analyses that underpin the PBAC deci-
sions. For example, patients should be made aware that
self-funding is an option, although in the case of TNFIs
this is impractical for most people. Interviewees proposed
that communication about the need to targeting use of
highly specialised medicines should extend to (potential)
patients and the public generally, and also to general prac-
titioners who could have an important role and contribu-
tion in this area. Increased community awareness and
understanding of the principle of quality-use-of-medi-
cines should be part of the overall educational strategy.
Interviewees had different views on whose responsibility
it was to provide information. The rheumatologist consid-
ered that information about the efficacy and safety of
TNFIs is most important and that the Australian Rheuma-
tology Association would be appropriate to provide ongo-
ing updates. Other proposed providers of information:
pharmacists, the  Medicare Australia (previously the
Health Insurance Commission), the PBS, the National
Prescribing Service (an independent educational organi-
sation funded by the Federal Government) [23], and the
consumer organisations.
Further investigation
The initial phase of the study has explored concerns of
individuals from the four relevant stakeholder groups.
Our study was not designed to support statistical general-
isability. Findings have established the basis for the next
phase of the study to explore perceptions of a wide range
of stakeholders that will be helpful in gaining a compre-
hensive and broad societal view of these significant devel-
opments of controlling access to high-cost medicines. A
written interview guide has been developed on the basis
of the findings of this phase for use in subsequent inter-
views. Diversity in sample characteristics and inclusion of
individuals who were engaged in the decision-making
process will expand understanding of the issues affecting
different members of the stakeholder groups and provide
some insight into the negotiations during the decision-
making process. Interviewees will include government
advisors, participants in the stakeholder consultation
process that formulated the arrangements for access to
TNFIs (who are in a position to comment on what actu-
ally occurred and what could be improved), rheumatolo-
gists and patients who have gone through the application
process, pharmaceutical company personnel, consumer
organisation representatives, and government administra-
tion staff. We anticipate that this broad range of interview-
ees will provide deep and rich insights to decision makers
regarding the future decision-making process and devel-
opment of national arrangements to manage access to
medicines from the perspectives of enhancing appropriate
access to effective and expensive medicines.
Conclusion
The PBS has developed a set of arrangements to target
access to expensive medicines such as the TNFIs in an
attempt to sustain this national drug reimbursement sys-
tem. Findings from this initial phase of the study high-
lighted a number of issues associated with the restricted
access to TNFIs. The principle of 'controlled access' to
TNFIs was supported in general by all interviewees each
from a different stakeholder group. However, it is clear
that some views, such as those concerning patient direct
participation or the varying responsibilities of each stake-
holder group, were different. The pre-determined ques-Publish with BioMed Central    and   every 
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tions appeared to adequately explore the key issues. A
thematic framework has now been developed on the basis
of the major themes that emerged from the interviews. We
believe there is a need for a more comprehensive explora-
tion, through a second phase of the study, to elicit differ-
ent perspectives across a variety of stakeholders, that will
in turn be helpful in guiding policy and practice around
national arrangements to manage access to high-cost
medicines.
Australia's Pharmaceutical Benefits Scheme, as part of the
National Medicines Policy, is committed to providing
access to cost-effective medicines to the community.
When resources are constrained, restricting access is an
inevitable outcome. Greater and more trust-based com-
munication and discussion among a wide range of stake-
holder groups will enhance community awareness and
support to limit access to effective medicines. Acceptable
but different approaches to control access and manage the
associated implications should be explored with the goal
of enhancing health outcomes for all.
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